On heels of pos­i­tive da­ta for AT­TR drug, Al­ny­lam looks to raise more cap­i­tal — near­ly $1B worth

A week af­ter pre­sent­ing pos­i­tive da­ta on its drug for treat­ing the heart fail­ure con­di­tion called transthyretin-me­di­at­ed amy­loi­do­sis (AT­TR) with car­diomy­opa­thy, Al­ny­lam wants to get al­most $1 bil­lion in new mon­ey.

The com­pa­ny an­nounced that it was of­fer­ing a $900 mil­lion prin­ci­pal amount of con­vert­ible se­nior notes due 2027. Con­vert­ible notes are short-term debt that con­verts in­to eq­ui­ty.

“The of­fer­ing of the notes is sub­ject to mar­ket and oth­er con­di­tions and there can be no as­sur­ance as to whether or when the of­fer­ing may be com­plet­ed, or as to the ac­tu­al size or terms of the of­fer­ing,” the com­pa­ny said in a press state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER